← Latest news 
Bombay High Court bars Meghmani Lifesciences from using Esiraft over confusion with Sun Pharma
Economy
Published on 24 April 2026
Court says Esiraft and Raciraft sound too alike
Sun Pharmaceutical has won a trademark dispute in Bombay High Court, which barred Meghmani Lifesciences from using the drug mark “Esiraft.” The court accepted Sun’s claim that Meghmani’s “Esiraft” is visually and phonetically similar to Sun’s “Raciraft,” creating a strong likelihood of consumer confusion and amounting to infringement and passing off.
- Bombay High Court restrained Meghmani from using “Esiraft”
- Marks were found visually and phonetically similar
- Decision backed Sun Pharma’s infringement and passing off claims
- Court ruled consumer confusion likely
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times